THE ROLE OF DOCETAXEL AS FIRST-LINE CHEMOTHERAPY ON PSA LEVEL AND QOL IN CRPC PATIENTS

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

PDF
Published 2024-05-10
Kurnia Penta Seputra Pradana Nurhadi Hikmat Satria

Abstract

Objective: Prostate cancer is the second most common cancer in men and the fifth leading cause of death worldwide. 10-20% of cases can progress to a more aggressive stage called castration-resistant prostate cancer (CRPC) with a higher death rate. Clinical guidelines recommend docetaxel as first-line chemotherapy and evaluated using the PSA test. This study aims to investigate the effect of docetaxel chemotherapy on PSA levels in CRPC. Material & Methods: A retrospective study was conducted from January 2016 until August 2022 according to the medical records database Saiful Anwar Hospital. There were 16 patients who met the inclusion criteria, including male patients with a diagnosis of CRPC who received castration therapy and found an increase in PSA 3 times of nadir or found 2 or more bone metastatic lesions or soft tissue lesions > 2 cm, received 6 series of docetaxel chemotherapy, and have a PSA data was performed before and after chemotherapy. Statistical analysis was performed using a differential T-test. Results: The results, obtained were significantly different (p<0.05) on the average PSA (log) pre-post chemotherapy, visual analog scale (VAS), and quality of life, and not significantly different on BMI pre-post chemotherapy. Conclusion: 6 cycles of docetaxel chemotherapy resulted in a decrease in PSA levels of CRPC significantly. It showed an excellent response to docetaxel chemotherapy in managing CRPC patients. Limitations of this study were specifically the retrospective cohort study model and the ability to reduce PSA levels in assessing the prognosis of CRPC. Keywords: Castration-resistant prostate cancer, chemotherapy, docetaxel, prostate-specific antigen.


##plugins.themes.bootstrap3.article.details##

Keywords

Castration-resistant prostate cancer, chemotherapy, docetaxel, prostate-specific antigen

References

Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, et al. Metastatic castration resistant prostate cancer: Current strategies of management in the Middle East. Crit Rev Oncol Hematol. 2014 Apr; 90(1): 36–48.

Thomas BM, Smith C, Evans J, Button MR, Kumar S, Palaniappan N, et al. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Med Oncol. 2013 Dec 12;30(4):719.

DP P. Practical guide to the use of chemotherapy in castration resistant prostate cancer. Can J Urol. 2014; (21): 77–83.

Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study. J Clin Oncol. 2008 Jan 10; 26(2): 242–5.

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021 Feb; 79(2): 263–82.

Kumon H, Sasaki K, Ariyoshi Y, Sadahira T, Ebara S, Hiraki T, et al. Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy. Clin Med Insights Oncol. 2015 Jan 23; 9: CMO.S23252.

Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 Nov; 65(11): 1180–92.

Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. N Engl J Med. 2004 Oct 7; 351(15): 1513–20.

Pei X, Wu K, Sun Y, Gao X, Gou X, Xu J, et al. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium. Urol Oncol Semin Orig Investig. 2020 Jan; 38(1): 2.e11-2.e17.

Francini E, Petrioli R, Rossi G, Laera L, Roviello G. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. Tumor Biol. 2014 Nov 7; 35(11): 10601–7.

Dickinson P, Malik J, Slevin F, Sivanandan A, Clarke N, Choudhury A & ET. Timing of PSA response to guide cessation of docetaxel in prostate cancer. J Clin Oncol. 2013 ;31.

Gomella LG, Petrylak DP & SB. Current management of advanced and castration resistant prostate cancer. Can J Urol. 2014; 21: 1–6.

Song L, Zhou X, Li X. Phase II trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer. Mol Clin Oncol. 2015 Jul; 3(4): 865–8.

Nader R, El Amm J, Aragon-Ching J. Role of chemotherapy in prostate cancer. Asian J Androl. 2018; 20(3): 221.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med. 2004 Oct 7; 351(15): 1502–12.

Section
Articles
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University